E-cadherin, b-catenin and topoisomerase II expression in rhabdomyosarcomas

Journal of B.U.ON.

Volumn 14, Issue 2, 2009, Pages 323-324

  Gogou, P N ^a   Batistatou, A ^a   Pakos, Emilios E ^a,c   Apostolikas, N ^b   Stefanou, D ^a   Tsekeris, P G ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

^b SAINT SAVVAS HOSPITAL   (Greece)

^c NONE   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; DNA TOPOISOMERASE (ATP HYDROLYSING); UVOMORULIN;

ADJUVANT CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURGERY; HUMAN; IMMUNOHISTOCHEMISTRY; LETTER; PROGNOSIS; PROTEIN EXPRESSION; RHABDOMYOSARCOMA; TUMOR VOLUME;

ADULT; BETA CATENIN; CADHERINS; DNA TOPOISOMERASES, TYPE II; HUMANS; IMMUNOENZYME TECHNIQUES; PROGNOSIS; RHABDOMYOSARCOMA;

EID: 67651052750     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (5)

1. Sato H, Hasegawa T, Abe Y, Sakai H, Hirohashi S. Expression of E-cadherin in bone and soft tissue sarcomas: a possible role in epithelial differentiation. Hum Pathol 1999; 30: 1344-1349. (Pubitemid 29534297)
2. Hasegawa T, Yokoyama R, Matsuno Y, Shimoda T, Hirohashi S. Prognostic significance of histologic grade and nuclear expression of beta-catenin in synovial sarcoma. Hum Pathol 2001; 32: 257-263. (Pubitemid 32246798)
3. Oda Y, Ohishi Y, Saito T et al. Nuclear expression of Y-box-binding protein-1 correlates with P-glycoprotein and topoisomerase II alpha expression, and with poor prognosis in synovial sarcoma. J Pathol 2003; 199: 251-258. (Pubitemid 36176032)
4. Charrasse S, Comunale F, Gilbert E, Delattre O, Gauthier-Rouvière C. Variation in cadherins and catenins expression is linked to both proliferation and transformation of rhabdomyosarcoma. Oncogene 2004; 23: 2420-2430. (Pubitemid 38496797)
5. Coffin CM, Rulon J, Smith L, Bruggers C, White FV. Pathologic features of rhabdomyosarcoma before and after treatment: a clinicopathologic and immunohistochemical analysis. Mod Pathol 1997; 10: 1175-1187.